Trial intelligence / Profile preview

TZP-102 for diabetic gastroparesis symptoms

2012-002576-14Phase 2Terminated

Sponsor
Tranzyme Pharma
Start
Jul 2012
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial in diabetic gastroparesis comparing TZP-102 with Placebo (2 arms). Primary endpoint: Change from baseline in GSDD symptom scores. Started Jul 2012; status: terminated.

02

Drugs

TZP-102
03

Conditions

diabetic gastroparesis

Beyond the preview

Go deeper on 2012-002576-14.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-002576-14.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call